Evidence map›Paper›PMID 41630508›Full record

ArticleThe Australasian journal of dermatology2026

Vulval Lichen Sclerosus Associated With Immune Checkpoint Inhibitor Therapy: A Case Series of 11 Patients.

Sophie Walter, Francesca Watts, Raquel Ruiz Araujo, Thevaki Wain, Amanda Glanz, Diona Damian, Matteo S Carlino, Alexander M Menzies, Georgina V Long, Linda K Martin

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Australasian journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sophie WalterSchool of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.ORCID https://orcid.org/0000-0001-6003-8914
Francesca WattsDepartment of Diagnostic Oncology and Tissue Pathology, Royal Prince Alfred Hospital, Sydney, Australia.
Raquel Ruiz AraujoFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0003-0478-3754
Thevaki WainDermatology Department, Royal Prince Alfred Hospital, Sydney, Australia.
Amanda GlanzFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0002-3356-1643
Diona DamianFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0002-2857-1775
Matteo S CarlinoFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0002-7861-4104
Alexander M MenziesFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0001-5183-7562
Georgina V LongFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0001-8894-3545
Linda K MartinSchool of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.ORCID https://orcid.org/0000-0001-9519-7077

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There have only been a limited number of case reports that have described vulval lichen sclerosus in patients receiving immune checkpoint inhibitor (ICI) therapy. We describe 11 cases of vulval lichen sclerosus in patients with melanoma treated with ICIs, and in nine of these cases, the lichen sclerosus symptoms began after ICI commencement. This represents the largest reported series to date and highlights the need for clinician awareness of this potential immune-related adverse effect.

Indexed as

Immune Checkpoint InhibitorsMelanomaSkin NeoplasmsVulvar Lichen SclerosusAgedAged, 80 and overFemaleHumansMiddle AgedImmune Checkpoint Inhibitorsadverse effectdermatologygenitalimmune checkpoint inhibitorlichen sclerosusmelanomavulval

Identifiers

PMID41630508
PMCPMC13176800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.